Review of current methods of diagnosis and treatment of locally advanced urothelial bladder cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aggressive disease course, recurrences, and deterioration of patients’ quality of life remain significant challenges in the treatment of bladder cancer. Determining the indications for systemic therapy or radical treatment, the early detection, and the optimal timing for initiating adjuvant therapy are all crucial aspects in the management of urothelial carcinoma. The analysis of the literature on changes in diagnostics and therapeutic approaches to urothelial bladder cancer according to disease stage is presented in the article.

Full Text

Restricted Access

About the authors

Tata A. Dmitrieva

FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: arust_tata@mail.ru
ORCID iD: 0009-0006-4992-5487

oncologist, Department of Chemotherapy

Russian Federation, 117997, Moscow, Bolshaya Serpukhovskaya St., Building 27

Anatoly Yu. Popov

FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation

Email: popov_63@mail.ru
ORCID iD: 0000-0001-6267-8237

Ph.D., Head of Department of Chemotherapy

Russian Federation, 117997, Moscow, Bolshaya Serpukhovskaya St., Building 27

Alexander A. Gritskevich

FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation; Peoples' Friendship University of Russia

Email: arust_tata@mail.ru
ORCID iD: 0000-0002-5160-925X

Ph.D., MD, Head of the Department of Urology, FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation; professor, Department of Urology and Operative Nephrology with a course of oncourology of Peoples' Friendship University of Russia, Ministry of Education and Science of the Russian Federation

Russian Federation, 117997, Moscow, 27 Bolshaya Serpukhovskaya St.; 117198, Moscow, 6 Miklukho-Maklaya St

Vladislav A. Makarov

FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation

Email: arust_tata@mail.ru
ORCID iD: 0000-0001-9838-4759

Ph.D., oncologist, Department of Chemotherapy

Russian Federation, 117997, Moscow, Bolshaya Serpukhovskaya St., Building 27

Anton D. Simonov

FGBU A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation

Email: arust_tata@mail.ru
ORCID iD: 0000-0003-3202-6873

physician of the Department of telemedicine

Russian Federation, 117997, Moscow, Bolshaya Serpukhovskaya St., Building 27

Konstantin Yu. Ryabov

NAKFF Clinic; Central Asian Medical University

Email: arust_tata@mail.ru
ORCID iD: 0000-0001-6891-4667

oncologist, surgeon, NAKFF Clinic; Honorary Professor, Central Asian Medical University

Russian Federation, 109089, Moscow, Ugreshskaya St., Building 2, Building 7; Fergana, Uzbekistan

References

  1. IARC. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2020. Access date August 2023
  2. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: P.A. Herzen Moscow Medical Research Institute − branch of the Federal State Budgetary Institution «NMITS of Radiology» of the Ministry of Health of the Russian Federation. 2022. fig. 252 p. Russain (Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022. илл. 252 с.).
  3. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106–119.
  4. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, Mizutani Y, Koga H, Okajima E, Okuyama A., Japanese Urological Association. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009;16(1):64-9.
  5. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3(6):327–40.
  6. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016;70(3):458–66.
  7. Zeegers MP, Swaen GM, Kant I, Goldbohm RA, van den Brandt PA. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med. 2001;58(9):590–96.
  8. Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A. 1975;72(6):2423–27.
  9. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447–461.
  10. Davis R, Jones JS, Barocas DA et al.; American Urological Association. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 suppl):2473-2481.
  11. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.
  12. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.
  13. Dobruch J., Herr H. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int. 2009;104:170–174. doi: 10.1111/j.1464-410X.2009.08654.x.
  14. Mori K., D’Andrea D., Enikeev D.V., Egawa S., Shariat S.F. En bloc resection for nonmuscle invasive bladder cancer: Review of the recent literature. Curr. Opin. Urol. 2020;30:41–47. doi: 10.1097/MOU.0000000000000697.
  15. Rimberg D.C., Shah A., Inman B.A. En Bloc Resection of Bladder Tumors: Style or Substance? Eur. Urol. 2020;78:570–571. doi: 10.1016/j.eururo.2020.05.019.
  16. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM et al. EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461.
  17. Oosterlinck W, Lobel B, Jakse G, Malmström P-U, Stöckle M, Sternberg C et al. Guidelines on bladder cancer. Eur Urol. 2002;41(2):105–112.
  18. Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive Urothelial bladder Cancer. Eur Urol Oncol. 2018;1(5):403–410.
  19. Gore JL, Saigal CS, Hanley JM, Schonlau M, Litwin MS, Urologic Diseases in America Project Variations in reconstruction after radical cystectomy. Cancer. 2006;107(4):729–737
  20. Romagnoli D, Schiavina R, Bianchi L, Borghesi M, Chessa F, Mineo Bianchi F et al. Is fast track protocol a safe tool to reduce hospitalization time after radical cystectomy with ileal urinary diversion? Initial results from a single high-volume Centre. Arch Ital Urol Androl. 2020;91(4):230–236.
  21. Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh Q-D et al. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014;66(3):569–576.
  22. Romagnoli D, Bianchi FM, Corsi P, D’Agostino D, Giampaoli M, Bianchi L et al. Robot-assisted radical cystectomy with Intracorporeal Orthotopic Ileal Neobladder: a safe strategy in elderly patients? Results of propensity score matching in a single high-volume center. Surg Technol Int. 2019;34:302–309.
  23. Bianchi FM, Romagnoli D, D’Agostino D, Corsi P, Giampaoli M et al. Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience. Cent European J Urol. 2019;72(2):113–120.
  24. Porreca A, Chessa F, Romagnoli D, Salvaggio A, Cafarelli A, Borghesi M et al. Robot assisted radical cystectomy with totally intracorporeal urinary diversion: initial, single-surgeon’s experience after a modified modular training. Minerva Urol Nefrol. 2018;70(2):193–201.
  25. Davis RB, Farber NJ, Tabakin AL, Kim IY, Elsamra SE. Open versus robotic cystectomy: comparison of outcomes. Investig Clin Urol. 2016;57(Suppl 1):S36–S43.
  26. Shen Z, Sun Z. Systematic review and meta-analysis of randomised trials of perioperative outcomes comparing robot-assisted versus open radical cystectomy. BMC Urol. 2016;16(1):59.
  27. SylvesterRJ, OosterlinckW, Van Der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.J Urol. 2004;171(6 pt 1):2186-2190.
  28. Doherty AP, Trendell-Smith N, Stirling R et al. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int. 1999;83(4):420-423. doi: 10.1046/j.1464-410x.1999.00951.x
  29. Messing EM, Tangen CM, Lerner SP et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial.JAMA. 2018;319(18):1880-1888. doi:10. 1001/jama.2018.4657
  30. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615-625. doi:10.1038/ s41585-018-0055-4
  31. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.J Urol. 2005;174(1):86-91
  32. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56-64.
  33. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3): iii40-iii48.
  34. Babjuk M, Böhle A, Burger M et al. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447-461.
  35. Witjes JA, Compérat E, Cowan NC et al.; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-792.
  36. Westergren DO, Gårdmark T, Lindhagen L, Chau A, Malmström PUA. A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014.J Urol. 2019;202(5):905-912.
  37. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349 (9):859-866. doi: 10.1056/NEJMoa022148
  38. Yin M, Joshi M, Meijer RP et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708-715. doi:10.1634/ theoncologist.2015-0440
  39. Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438. doi:10.1200/ JCO.2011.34.8433.
  40. Necchi A, Raggi D, Gallina A et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439-446. doi:10. 1016/j.eururo.2019.10.026
  41. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study Crossref DOI link: https://doi.org/10.1016/S1470-2045(23)00539-9 Published Print: 2024-01 Update policy: https://doi.org/10.1016/elsevier_cm_policy
  42. Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West CML, Lewis R, Hussain SA, James ND, Huddart R, Hoskin P; BC2001 and BCON investigators. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0. PMID: 33539743; PMCID: PMC7851111.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Choice of treatment for UTUC depending on the extent of the process

Download (132KB)
Indexing metadata
3. Fig. 2. Frequency of development of the most frequently encountered adverse events in VESPER management

Download (96KB)
Indexing metadata

Copyright (c) 2025 Bionika Media